Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedMar 8, 2023Daptomycin for Injection 350 mg/vialCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0381-2023Class IITerminatedMar 8, 2023Clopidogrel Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0380-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 30 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0379-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0378-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 15 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0377-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0376-2023Class IITerminatedMar 8, 2023BusPIRone Hydrochloride Tablets USP 7.5 mgCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0375-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 80 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0374-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 40 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0373-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USP 20 mg*CGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0372-2023Class IITerminatedMar 8, 2023Atorvastatin Calcium Tablets USPCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0371-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0370-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0369-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0368-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0367-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0366-2023Class IITerminatedMar 8, 2023Aripiprazole TabletsCGMP Deviations: recalling drug products following an FDA inspection.Accord Healthcare, Inc. · D-0365-2023Class IITerminatedMar 8, 2023Sterile Water for InjectionCGMP Deviations: Potential product carryover.Nephron Sc Inc · D-0364-2023Class IIITerminatedMar 8, 2023Fentanyl 1Subpotent DrugSCA Pharmaceuticals · D-0363-2023Class IITerminatedMar 8, 2023Phenylephrine HCl in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0362-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0361-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0360-2023Class IITerminatedMar 8, 2023Phenylephrine HCl InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0359-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0358-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0357-2023Class IITerminatedMar 8, 2023Norepinephrine Bitartrate in 0.9% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0356-2023Class IITerminatedMar 8, 2023Diltiazem HCl in 0.7% Sodium Chloride InjectionLack of Assurance of SterilityNephron Sterile Compounding Center LLC · D-0355-2023Class IIITerminatedMar 8, 2023Gabapentin TabletsPresence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.Sciegen Pharmaceuticals Inc · D-0354-2023Class IITerminatedMar 8, 2023Levothyroxine Sodium TabletsSub-Potent Drug: Out of specification for assay at the 24 month interval.Alvogen, Inc · D-0353-2023Class IIITerminatedMar 8, 2023BD-102 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0352-2023Class IIITerminatedMar 8, 2023Avicel PH-200 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0351-2023Class IIITerminatedMar 8, 2023Avicel PH- 102 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0350-2023Class IIITerminatedMar 8, 2023Avicel PH- 101 NFFailed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.DuPont Nutrition USA, Inc · D-0349-2023Class IITerminatedMar 1, 2023Warfarin Sodium TabletsFailed Impurities/Degradation SpecificationsRising Pharmaceuticals · D-0348-2023Class IICompletedMar 1, 20230.9% Sodium Chloride InjectionLack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an...B. Braun Medical Inc. · D-0347-2023Class IICompletedMar 1, 20230.9% Sodium Chloride InjectionLack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL¿ Plus IV Container product due to the possibility of an...B. Braun Medical Inc. · D-0346-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0345-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0344-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0343-2023Class IITerminatedMar 1, 2023TIROSINT - SOLSubpotent DrugIbsa Pharma Inc · D-0342-2023

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.